Welireg (belzutifan)

pCPA File Number: 23197

Negotiation Status:

Under consideration for negotiation

Indication(s):

For the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

Sponsor/Manufacturer:

Merck Canada Inc.

CDA-AMC Project Number:

PC0386-000

pCPA Engagement Letter Issued:

Not Applicable

Negotiation Process Concluded:

Not Applicable